JP2022505525A5 - - Google Patents

Info

Publication number
JP2022505525A5
JP2022505525A5 JP2021521800A JP2021521800A JP2022505525A5 JP 2022505525 A5 JP2022505525 A5 JP 2022505525A5 JP 2021521800 A JP2021521800 A JP 2021521800A JP 2021521800 A JP2021521800 A JP 2021521800A JP 2022505525 A5 JP2022505525 A5 JP 2022505525A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
groups
aryl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057682 external-priority patent/WO2020086732A1/en
Publication of JP2022505525A publication Critical patent/JP2022505525A/ja
Publication of JP2022505525A5 publication Critical patent/JP2022505525A5/ja
Pending legal-status Critical Current

Links

JP2021521800A 2018-10-24 2019-10-23 Nlrp活性に関連する状態を治療するための化合物及び組成物 Pending JP2022505525A (ja)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201862749730P 2018-10-24 2018-10-24
US201862749725P 2018-10-24 2018-10-24
US201862749712P 2018-10-24 2018-10-24
US62/749,712 2018-10-24
US62/749,730 2018-10-24
US62/749,725 2018-10-24
US201862751386P 2018-10-26 2018-10-26
US201862751380P 2018-10-26 2018-10-26
US201862751301P 2018-10-26 2018-10-26
US62/751,386 2018-10-26
US62/751,380 2018-10-26
US62/751,301 2018-10-26
US201962801930P 2019-02-06 2019-02-06
US62/801,930 2019-02-06
US201962802654P 2019-02-07 2019-02-07
US201962802637P 2019-02-07 2019-02-07
US62/802,637 2019-02-07
US62/802,654 2019-02-07
US201962812813P 2019-03-01 2019-03-01
US201962812517P 2019-03-01 2019-03-01
US201962812794P 2019-03-01 2019-03-01
US62/812,794 2019-03-01
US62/812,517 2019-03-01
US62/812,813 2019-03-01
PCT/US2019/057682 WO2020086732A1 (en) 2018-10-24 2019-10-23 Compounds and compositions for treating conditions associated with nlrp activity

Publications (2)

Publication Number Publication Date
JP2022505525A JP2022505525A (ja) 2022-01-14
JP2022505525A5 true JP2022505525A5 (cg-RX-API-DMAC7.html) 2022-10-24

Family

ID=68583498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521800A Pending JP2022505525A (ja) 2018-10-24 2019-10-23 Nlrp活性に関連する状態を治療するための化合物及び組成物

Country Status (5)

Country Link
US (1) US20230011652A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870565A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022505525A (cg-RX-API-DMAC7.html)
CN (1) CN113056451A (cg-RX-API-DMAC7.html)
WO (1) WO2020086732A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MX2021000660A (es) 2018-07-20 2021-03-25 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
WO2021009567A1 (en) 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Nlrp3 modulators
AU2020312800B2 (en) * 2019-07-17 2026-04-23 Zomagen Biosciences Ltd N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
CA3175729A1 (en) 2020-03-16 2021-09-23 Zomagen Biosciences Ltd Nlrp3 modulators
CN114539256B (zh) * 2020-11-20 2024-02-02 上海拓界生物医药科技有限公司 三环化合物及其医药用途
CN114516878B (zh) * 2020-11-20 2024-02-02 上海拓界生物医药科技有限公司 三环化合物及其医药用途
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN118475558A (zh) * 2021-12-22 2024-08-09 瑞石生物医药有限公司 一种磺酰脲类化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671817A (en) 1985-04-23 1987-06-09 E. I. Du Pont De Nemours And Company Herbicidal pyrazole sulfonamides
US4678498A (en) 1985-06-12 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US5017212A (en) 1986-03-20 1991-05-21 Takeda Chemical Industries, Ltd. Sulfonylurea compounds and herbicidal use
US4927453A (en) 1986-10-17 1990-05-22 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
EP0318620A1 (en) 1987-12-04 1989-06-07 E.I. Du Pont De Nemours And Company Herbicidal sulfonamides
AU7165591A (en) 1990-01-22 1991-08-05 E.I. Du Pont De Nemours And Company Herbicidal sulfonylureas
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
DK1270565T3 (da) * 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
BR0014003A (pt) * 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
US20030189215A1 (en) 2002-04-09 2003-10-09 Jong-Lam Lee Method of fabricating vertical structure leds
WO2006085815A1 (en) * 2005-02-11 2006-08-17 Astrazeneca Ab Thiazole derivatives, their process for their preparation and their use in therapy
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
MA44729A (fr) * 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
UA126675C2 (uk) * 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物

Similar Documents

Publication Publication Date Title
JP2022507065A5 (cg-RX-API-DMAC7.html)
JP2020528889A5 (cg-RX-API-DMAC7.html)
JP2022507506A5 (cg-RX-API-DMAC7.html)
JP2020537657A5 (cg-RX-API-DMAC7.html)
JP2022506898A5 (cg-RX-API-DMAC7.html)
JP2019519598A5 (cg-RX-API-DMAC7.html)
JP2019515952A5 (cg-RX-API-DMAC7.html)
EP1838320B1 (en) Cxcr4 antagonists for the treatment of medical disorders
JP2019518071A5 (cg-RX-API-DMAC7.html)
TW570917B (en) Trisubstituted 1,3,5-triazine derivatives
JP6608918B2 (ja) P38キナーゼ阻害剤としてのジアリール尿素誘導体
CN113264921B (zh) 作为激酶抑制剂的吡唑基-脲
JP2022507505A5 (cg-RX-API-DMAC7.html)
JP2024512154A5 (cg-RX-API-DMAC7.html)
JP6464384B2 (ja) キナーゼ阻害剤
HRP20251344T1 (hr) SPOJEVI I PRIPRAVCI ZA LIJEČENJE STANJA POVEZANIH S AKTIVNOŠĆU NLRP-a
JP2022531609A (ja) 新規メチルキナゾリノン誘導体
RU2008141368A (ru) Новые гетероциклические соединения замещенного пиридина с антагонистической активностью схсr3
US20160002174A1 (en) CXCR4 Antagonists for the Treatment of Medical Disorders
US20080227799A1 (en) CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
JP2021530536A (ja) インターロイキン−1活性の阻害剤としてのスルホニル尿素化合物
JP2010540508A5 (cg-RX-API-DMAC7.html)
US20090099194A1 (en) CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders
JP2014503574A5 (cg-RX-API-DMAC7.html)
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака